Industry News

- Read more about FDA Approves Taro’s Keveyis™ (dichlorphenamide) 50 mg Tablets for Primary Hyperkalemic and Hypokalemic Periodic Paralysis
Taro Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved Keveyis™ (dichlorphenamide) 50 mg Tablets for the treatment of primary hyperkalemic and hypokalemic periodic paralysis, a group of rare hereditary disorders that cause episodes of muscle weakness or paralysis.^[1] Keveyis is the first medicine approved by the FDA for the treatment of primary periodic paralysis, which is estimated to affect approximately 5,000 people in the United States.^[2]
- Read more about Hetero introduce Maball for NHL, CLL patients in India
Hetero Group, one of India’s leading generic pharmaceutical companies has recently announced the launch of its biosimilar ‘Rituximab’ under the brand name Maball in India. It will be marketed and distributed by Hetero Healthcare Limited, a group company of Hetero. Rituximab is recommended as the first-line treatment for NHL and is available in a single dose vial with two strengths – 100mg/10ml and 500mg/50ml.
- Read more about Dr Reddy's Labs introduce three medicines of Amgen in India
Dr Reddy's Laboratories has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, DRL will launch Kyprolis (carfilzomib), Blincyto (blinatumomab and Repatha (evolocumab) in India.
- Read more about Ajanta Pharma receives US FDA final approval for generic Singulair tablets
Ajanta Pharma Limited, a Rs.1,450 crore plus Mumbai based specialty focused pharmaceutical formulation company, has received final approval from the United States Food and Drug Administration (FDA) for its 3 Abbreviated New Drug Applications (ANDAs), montelukast tablets, 10mg, montelukast sodium chewable tablets, 4mg & 5mg and montelukast oral granules.
- Read more about Pharma Major Lupin starts Research centre in US
Pharma Major Lupin Limited (Lupin) today announced the opening of its new Center of Excellence for Inhalation Research in Coral Springs, Florida. Local and state leaders, including Florida Lieutenant Governor Carlos Lopez-Cantera, Florida Department of Economic Opportunity Director Jesse Panuccio, and Mayor Skip Campbell, were on site to celebrate the opening of Lupin’s new facility with a ribbon cutting ceremony.
- Read more about Sofgen's Nimodipine 30mg capsule receives US FDA approval
ANI Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, announced that its ANDA collaboration partner Sofgen, received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nimodipine 30mg capsules. ANI and Sofgen expect to begin shipping to customers this year.
- Read more about MedPlus launches 'Click. Pick & Save' service in Delhi
MedPlus has recently launched e-commerce service ‘Click. Pick & Save’ in Delhi and NCR area. With this launch, the service is available in all the top metro areas of the country except Mumbai.
- Read more about EMA committee recommends Merck's antibiotic Zerbaxa approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of Merck's investigational antibiotic Zerbaxa (ceftolozane and tazobactam). This is used for the treatment of the complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections in adults.
- Read more about Unichem Pharmaceuticals issues Voluntary Recall of hypertension drugs
Unichem Pharmaceuticals (USA) is a wholly-owned subsidiary of the company, is voluntarily recalling one lot of Hydrochlorothiazide Tablets 25 mg 1000-count bottle at the consumer level, US Food and Drug Administration (USFDA) said in a statement.
- Read more about Vodafone Business Services launch 'dCare Smart'
Vodafone Business Services (VBS) collaborate with Diabetacare to launch dCare Smart, a device that helps people manage diabetes better. The device transmits blood sugar results to a secure Diabetacare server, where they are constantly monitored by diabetes specialist clinicians at the Diabetacare’s Diabetes Management Centre (DMC). dCare Smart is paired with the back-end clinical servers which connect directly to the electronic medical record system, wherein access is given to patients and their caregivers to keep them informed and better manage the condition.